Secukinumab, an interleukin-17A inhibitor (IL-17A), represents a newer class of biological medications approved by the Food and Drug Administration in 2015 for the treatment of plaque psoriasis and axial spondyloarthritis [1]. Here, IL17A is linked to psoriasis vulgaris.